Detalhe da pesquisa
1.
Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
BMC Cancer
; 21(1): 499, 2021 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33947352
2.
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Ann Hematol
; 93(8): 1371-80, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24687382
3.
Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients.
J Gynecol Oncol
; 32(2): e18, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33327048
4.
Correlation among DCE-MRI measurements of bone marrow angiogenesis, microvessel density, and extramedullary disease in patients with multiple myeloma.
Am J Hematol
; 87(8): 837-9, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22718413
5.
Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.
PLoS One
; 10(9): e0137552, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26379028